The private label CBD gummies market is poised for substantial growth, with projections indicating it will reach USD 1,382.2 million by 2036, according to a new report from Future Market Insights (FMI). Valued at USD 598.9 million in 2025 and expected to hit USD 646.2 million in 2026, the market is forecast to expand at a compound annual growth rate (CAGR) of 7.9% over the next decade. This expansion is fueled by wellness brands increasingly turning to outsourced manufacturing to launch CBD-infused edible products more efficiently and with lower capital investment.
As competition intensifies in the functional wellness industry, companies are opting for private label CBD gummies to enter the market without investing in extraction facilities or confectionery manufacturing infrastructure. The white label service model, which accounts for 46.2% of market demand in 2026, is particularly popular due to its shorter commercialization timelines and reduced formulation costs. This approach allows brands to focus on marketing and customer acquisition while leveraging established manufacturing processes.
Broad-spectrum CBD gummies are leading the market by spectrum type, capturing 42.8% of demand in 2026. Consumer preference for THC-free wellness products that retain multiple cannabinoids is driving this trend. As retailers enforce stricter product review procedures and consumers demand transparency, broad-spectrum formulations offer a balance between perceived benefits and regulatory simplicity.
Brand websites are the dominant sales channel, representing 39.6% of global demand in 2026. Direct-to-consumer platforms enable brands to control customer education, product positioning, and subscription programs. This channel also provides flexibility for updating compliance information, which is crucial as regulatory scrutiny over CBD products increases. Specialist wellness retailers and licensed cannabis outlets remain important for compliant distribution where permitted.
The United States is the fastest-growing market, with a projected CAGR of 8.5% through 2036, supported by a mature CBD ecosystem and a strong direct-to-consumer infrastructure. Other key markets include Canada (8.1% CAGR), the United Kingdom (7.8%), Germany (7.5%), and Australia (7.3%).
Key players in the market include CBD Nationwide, Extract Labs, cbdMD, Inc., Charlotte's Web Holdings, Inc., CV Sciences, Inc., Medterra CBD LLC, British Cannabis, Cannaray Limited, MediPharm Labs Corp., and Little Green Pharma Ltd. These companies compete on formulation expertise, manufacturing scalability, compliance support, and packaging capabilities.
Despite strong growth prospects, the market faces challenges such as regulatory complexity surrounding health claims, labeling requirements, and cannabinoid content verification. Differences in CBD regulations across countries can delay commercialization and increase costs. Nevertheless, trends such as customized formulations for sleep and relaxation, third-party laboratory testing, and sustainable packaging are shaping the industry's future.
FMI's report provides detailed forecasts and competitive benchmarking. For more information, visit the sample report or access the full report in PDF format here.
